Assessment of polymorphic metabolite data in bioavailability/bioequivalence studies – considerations and challenges
Main Article Content
Abstract
the influence of a polymorphic enzyme. This communication provides brief perspectives on the challenges and study design considerations for the assessment of polymorphic metabolite in BA/BE studies.
Downloads
Article Details
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
References
Colburn WA, Keefe DL. Bioavailability and bioequivalence: Average,
population and/or individual. J Clin Pharmacol 2000;40:559-60.
Yacobi A, Masson E, Moros D, Ganes D, Lapointe C, Abolfathi Z, et al.
Who needs individual bioequivalence studies for narrow therapeutic
index drugs? A case for warfarin. J Clin Pharmacol 2000;40:826-35.
Bialer M, Midha KK. Generic products of antiepileptic drugs: A
perspective on bioequivalence and interchangeability. Epilepsia
;51:941-50.
Zariffa NM, Patterson SD. Population and individual bioequivalence:
lessons from real data and simulation studies. J Clin Pharmacol
;41:811-22.
Zariffa NM, Patterson SD, Boyle D, Hyneck M. Case studies, practical
issues and observations on population and individual bioequivalence.
Stat Med 2000;19:2811-20.
Karalis V, Symillides M, Macheras P. Novel methods to assess
bioequivalence. Expert Opin Drug Metab Toxicol 2011;7:79-88.
Srinivas NR. Considerations for metabolite pharmacokinetic data in
bioavailability/bioequivalence assessments - Overview of the recent
trends. Arzneimittelforschng 2009;59:155-65.
Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J. The clinical
role of genetic polymorphisms in drug-metabolizing enzymes.
Pharmacogenomics J 2008;8:4-15.
Bijl MJ, Luijendijk HJ, van den Berg JF, Visser LE, van Schaik RH,
Hofman A, et al. Association between the CYP2D6*4 polymorphism and
depression or anxiety in the elderly. Pharmacogenomics 2009;10:541-7.
Ginsberg G, Smolenski S, Neafsey P, Hattis D, Walker K, Guyton KZ, et al.The influence of genetic polymorphisms on population variability in
six xenobiotic-metabolizing enzymes. J Toxicol Environ Health B Crit
Rev 2009;12:307-33.
Johansson I, Ingelman-Sundberg M. Genetic polymorphism and
toxicology-with emphasis on cytochrome p450. Toxicol Sci 2011;120:1-13.
Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450
enzymes and its clinical impact. Drug Metab Rev 2009;41:89-295.
Solans A, Izquierdo I, Donado E, Antonijoan R, Peña J, Nadal T, et al.
Pharmacokinetic and safety profile of rupatadine when coadministered
with azithromycin at steady-state levels: A randomized, open-label,
two-way, crossover, Phase I study. Clin Ther 2008;30:1639-50.
Katiyar S, Prakash S. Systematic review: Pharmacological profile,
efficacy and safety of rupatadine in allergic rhinitis. Primary Care Resp
J 2009;18:57-68.
Frick GS, Blum RA, Kovacs SJ, Lone. Prevalence of the slow metabolizer
(SM) phenotype and single dose pharmacokinetics (PK) of desloratadine
(DCL) in a population of healthy adults. Clin Pharmacol Ther 2004;75:9.
Available from: http://dx.doi.org/10.1016/j.clpt.2003.11.033 [Last
accessed on 2011 Jul 20].
Prenner B, Kim K, Gupta S, Khalilieh S, Kantesaria B, Manitpisitkul P, et al.
Adult and pediatric poor metabolisers of desloratadine: An assessment
of pharmacokinetics and safety. Expert Opin Drug Saf 2006;5:211-23.
Srinivas NR. Unsuspected polymorphic metabolism of rupatadine via its primary metabolite, desloratadine. Prim Care Respir J 2009;18:118-9.